ETFs Outperformed Managed Biotechnology Funds YTD-FBT Is the Leader
2014 YTD- ETFs Outperformed Managed Funds In Biotech In the past managed life science funds outperformed ETFs but this has reversed in 2014. Fidelity's flagship Select Biotechnology Portfolio (FBIOX) is up 10% YTD and 41.4% over one year, and 229.6% over 5 years. The fund is concentrated in...
Rayno Diagnostics and Tools Stocks: GHDX, ILMN, QGEN, RGDX.
Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and genetic tests. Many genetic...
BIO 2014 Update #1 Personalized Medicine-Megatrend Momentum Continues
Challenges Ahead But Sequencing Is A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum provided full day coverage...
Vertex (VRTX) Soars 42% On Cystic Fibrosis Breakthrough Update-1
Data To Be Submitted in Q4 For Approval Two Phase III studies with combination drug showed clinically significant improvements in lung function Rayno Life Science Pick and Deja Vu Trade Last April at the same BIO Conference we wrote about Phase II data from Vertex when biopharmaceutical stocks...
BIO International Convention San Diego, CA This Week
Biotech Stocks Weak After 30 Day Rally NASDAQ at 4365 We will be attending the 2014 BIO International Convention this week. We do not expect any major scientific developments but will try to keep you informed on any market moving events. Several hundred global companies will be exhibiting with...